Industry concerns are rising on the announcement of reimbursement cuts for the nonsteroidal anti-inflammatory drug ‘loxoprofen.’ The adequacy of its reimbursement as an antipyretic/analgesic for acute upper respiratory tract inflammation has not been recognized by the authorities in Korea, and its scope of prescriptions is set to be narrowed as a result. As reimbursement for this particular indication has rapidly increased since the COVID-19 pandemic, the losses felt by pharmaceutical companies are expected to be even greater.

According to industry sources on the 13th, the Health Insurance Review and Assessment Service concluded that only 2 out of the 3 indications for loxoprofen are eligible for reimbur